Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT: Hydroxyurea PK/PD dosing in pediatric Sickle Cell Anemia
NCT02286154Active, not recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2014
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 cohorts), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Time to Reach Maximum Tolerated Dose at 12 months. Started Oct 2014; status: active, not recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT02286154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286154.